New approaches for the treatment of Alzheimer's disease

被引：121
|
作者：
Fish, Paul V. [1 ,2 ]
Steadman, David [1 ]
Bayle, Elliott D. [1 ,2 ]
Whiting, Paul [1 ,3 ]
机构：
[1] UCL, Alzheimers Res UK UCL Drug Discovery Inst, Cruciform Bldg,Gower St, London WC1N 1E 6BT, England
[2] Francis Crick Inst, 1 Midland Rd, London NW1 1AT, England
[3] UCL, Dementia Res Inst, Cruciform Bldg,Gower St, London WC1N 1E 6BT, England
来源：
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2019年 / 29卷 / 02期
基金：
英国惠康基金; 英国工程与自然科学研究理事会; 英国医学研究理事会;
关键词：
Alzheimer's disease; Neurodegeneration; Neuroinflammation; Drug discovery pipeline; Symptomatic treatments; Disease modification; 5-HT6 RECEPTOR ANTAGONIST; DOUBLE-BLIND; AMYLOID HYPOTHESIS; CHOLINERGIC SYSTEM; TAU-AGGREGATION; MILD; EFFICACY; MODERATE; SAFETY; INHIBITOR;
D O I：
10.1016/j.bmcl.2018.11.034
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
Alzheimer's disease (AD) is the most prevalent chronic neurodegenerative disease. Current approved therapies are symptomatic treatments having some effect on cognitive function. Therapies that target beta-amyloid (A beta) have been the focus of efforts to develop a disease modification treatment for AD but these approaches have failed to show any clinical benefit so far. Beyond the 'A beta hypothesis', there are a number of newer approaches to treat AD with neuroinflammation emerging as a very active area of research based on risk gene analysis. This short review will summarize approved drug therapies, recent clinical trials and new approaches for the treatment of AD.
引用
收藏
页码：125 / 133
页数：9
相关论文
共 50 条
12345